Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06973564 · ClinicalTrials.gov registry record · Phase 1
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
A Phase 1 study of Advanced Solid Tumors, sponsored by Jacobio Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 294
- Enrollment target
- 4
- Study locations
NCT06973564: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Jacobio Pharmaceuticals Co..
NCT06973564 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 294 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06973564, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Jacobio Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 294 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
Primary Outcome
Number and proportion of patients who experience at least 1 dose-limiting toxicity (DLT) during the first 21 days of treatment. A DLT is defined as any toxicities that meet the criteria for a DLT assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 during the evaluation period at any dose.
Conditions Studied
Interventions
- DRUG JAB-23E73
Study Locations (4)
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University - St Louis
Ohio
- Cleveland Clinic Foundation - Cleveland
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What NCT06973564 shows while recruiting
NCT06973564 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JAB-23E73 is the first listed.
NCT06973564 reports a single indexed study location in Minnesota, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT06973564 about?
NCT06973564 is a clinical study titled "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration". This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
What is the current status of trial NCT06973564?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 294 participants. The study started on 2025-05-29. Estimated completion is 2028-02.
What conditions does trial NCT06973564 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06973564?
The interventions under investigation include: JAB-23E73 (DRUG).
Who is sponsoring clinical trial NCT06973564?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06973564 being conducted?
This trial has 4 study locations across Minnesota, Missouri, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06973564's enrollment target sits among peer trials
294 27th of 144 higher than 118 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI